Arvinas, Inc. (ARVN)
| Previous close | 34.00 |
| Open | 33.82 |
| Bid | 33.07 x 100 |
| Ask | 33.19 x 100 |
| Day's range | 32.93 - 33.83 |
| 52-week range | 13.57 - 53.08 |
| Volume | |
| Avg. volume | 766,688 |
| Market cap | 2.264B |
| Beta (5Y monthly) | 1.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.62 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.83 |
ZacksNovartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Investor's Business DailyBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.
- Reuters
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas to gain access to the U.S. biotech firm's experimental prostate cancer drug, Arvinas said on Thursday. Shares of Connecticut-based Arvinas rose more than 6% to $39 in premarket trade. The pact adds to Novartis' pursuit of cancer treatments after it launched a tender offer on Thursday to acquire German cancer drugmaker MorphoSys for an aggregate 2.7 billion euros ($2.9 billion).
